Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 38Colorectal Neoplasms 18Small Cell Lung Carcinoma 8Neoplasms 8Stomach Neoplasms 7Neoplasm Metastasis 5Biliary Tract Neoplasms 5Sarcoma, Ewing 4Rhabdomyosarcoma 4Recurrence 4Osteosarcoma 4Rectal Neoplasms 3Ovarian Neoplasms 3Cholangiocarcinoma 3Triple Negative Breast Neoplasms 2Solid Tumor 2Neuroblastoma 2Nasopharyngeal Carcinoma 2Metastatic Pancreatic Adenocarcinoma 2Head and Neck Neoplasms 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Wilms Tumor 1Weight Loss 1Somatostatinoma 1Solid Tumor Cancer 1Small Cell Lung Cancer Extensive Stage 1

Interventions

irinotecan sucrosofate 1Oxaliplatin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Small Intestine Cancer × irinotecan sucrosofate × Clear all
NCT07060014 2025-07-11

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

The Methodist Hospital Research Institute

Phase 1 Not yet recruiting
22 enrolled
Gastrointestinal

Advanced Small Intestine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡